Drugs / Adrenocorticotropic Hormone
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03727776 | Aug 2019 → Jul 2023 | proliferative vitreoretinopathy | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02348905 | Mar → Jul 2015 | skin sarcoidosis | Albany Medical College | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02290444 | Aug 2013 → Nov 2018 | multiple sclerosis | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase not applicable3 trials · 1 missed | ||||||
| — | NCT04808856 | Apr 2021 → Apr 2022 | gout | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| — | NCT04461535 | Jul 2020 → Feb 2023 | primary aldosteronism | Chongqing Medical University | Completed | Missed primary |
| — | NCT02030028 | Nov 2014 → Jun 2022 | rheumatoid arthritis | Dana Ascherman | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07005154 Background | Jun 2025 → May 2032 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adrenocorticotropic hormone | “Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.” NCT02030028 ↗6“ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.” NCT02348905 ↗ |
| Known as | ACTHAR Gel | “ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.” NCT02348905 ↗ |
| Action | Activate | “it may also activate melanocortin receptors” NCT02348905 ↗ |
| Modality | Peptide | “Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone” NCT03727776 ↗ |
| Route | Subcutaneous | “Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.” NCT02030028 ↗ |